Stereotaxis to Report Second Quarter 2014 Financial Results on August 4, 2014
July 28 2014 - 6:30AM
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will
release financial results for its 2014 second quarter ended June
30, 2014 on Monday, August 4, 2014 after the close of the U.S.
financial markets. The Company will host a conference call and
webcast at 4:30 p.m. Eastern Time that day to discuss the Company's
results and corporate developments.
What: |
Stereotaxis second quarter 2014 financial
results conference call |
|
|
When: |
Monday, August 4th at 4:30 p.m. Eastern Time
(1:30 p.m. PT) |
|
|
Dial In Number: |
888-287-5563 (US and Canada) |
|
719-457-2645 (International) |
|
|
Webcast: |
To access the live and replay webcast, please
visit the investor relations section of Stereotaxis' website at
www.stereotaxis.com |
|
|
Call Replay: |
A replay of the call will be available
approximately one hour following the end of the call through 11:59
p.m. ET on Monday, August 11, 2014. |
|
|
Replay Numbers: |
888-203-1112 (US and Canada) |
|
719-457-0820 (International) |
|
Replay passcode: 7713816# |
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in
the development of robotic cardiology instrument navigation systems
designed to enhance the treatment of arrhythmias and coronary
disease, as well as information management solutions for the
interventional lab. Over 100 issued patents support the Stereotaxis
platform, which helps physicians around the world provide
unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Stereotaxis' core Epoch™ Solution
includes the Niobe® ES Remote Magnetic Navigation system, the
Odyssey® portfolio of lab optimization, networking and patient
information management systems and the Vdrive™ Robotic Navigation
system and consumables.
The core components of Stereotaxis systems have received
regulatory clearance in the U.S., European Union, Canada, China,
Japan and elsewhere. The V-Sono™ ICE catheter manipulator has
received U.S. clearance, and the V-Loop™ variable loop catheter
manipulator and V-CAS™ catheter advancement system have been
submitted for review by the U.S. Food and Drug Administration. For
more information, please visit www.stereotaxis.com
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe," "estimate," "project," "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its ability to continue to manage
expenses and cash burn rate at sustainable levels, its ability to
continue to work with lenders to extend, repay or refinance
indebtedness on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, the outcome
of various shareholder litigation filed against Stereotaxis,
competitive factors, changes resulting from the recently enacted
healthcare reform in the U.S., including changes in government
reimbursement procedures, dependence upon third-party vendors,
timing of regulatory approvals, and other risks discussed in the
Company's periodic and other filings with the Securities and
Exchange Commission. By making these forward-looking statements,
the Company undertakes no obligation to update these statements for
revisions or changes after the date of this release. There can be
no assurance that the Company will recognize revenue related to its
purchase orders and other commitments in any particular period or
at all because some of these purchase orders and other commitments
are subject to contingencies that are outside of the Company's
control. In addition, these orders and commitments may be revised,
modified, delayed or canceled, either by their express terms, as a
result of negotiations, or by overall project changes or
delays.
CONTACT: Company Contact:
Marty Stammer
Chief Financial Officer
314-678-6155
Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com